Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /dom76025/wp-includes/functions.php on line 6121
U.S. FDA Approves Ustekinumab Biosimilar for Psoriasis, PsA - The Dermatology Digest
Subscribe
Search

U.S. FDA Approves Ustekinumab Biosimilar for Psoriasis, PsA

The U.S. Food and Drug Administration approved Biocon Biologics’ Yesintek, Bmab 1200 Biosimilar to ustekinumab (Stelara, J & J).

Yesintek, a monoclonal antibody, is approved for the treatment of plaque psoriasis, psoriatic arthritis.  Crohn’s disease, and ulcerative colitis.

Biocon Biologics Ltd had previously announced  that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Yesintek,in the United States of America no later than on February 22, 2025, upon approval from the U.S. FDA.

Print Friendly, PDF & Email